Blood Coagulants Market of Middle East & Africa: By Types, Indication – Predict Till 2023

Middle East and Africa Blood Coagulants Market Information, by Drug Class (Coagulation Factor (Plasma-derived Factors (Factor VIII and IX, Von Willebrand Disease Factor, Prothrombin Complex and others) and Recombinant Coagulation Factors (Factor VIII and IX, Von Willebrand Disease Factor, Prothrombin Complex and others)), Vitamin K analogues, Fibrinogen Analogues and others), by Clinical Indications (Accidents, Surgery, Hemophilia and Others) - Forecast till 2022. Blood Coagulant Market of Middle East & Africa’s growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. In the Middle East and Sub-Saharan Africa, bleeding disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/2743 . 

Coagulation is a process in which blood changes from a liquid to a gel, forming a blood clot. It is a natural process occurs to heal a lesion/wound/cut and stop the bleeding.    

According to the Annual Global Survey of World Federation of Hemophilia (WFH), in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 had bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% patients were under 4 years. A research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia in Saudi Arabia and dominant in male: 1: 5000 to 10,000. Whereas, prevalence rate of hemophilia B: 1: 34,500 male patients.

The market is expected to grow at the CAGR of 9.5% during the forecast period 2017-2023. As per a study published in Blood Coagulation Fibrinolysis journal in 2016, Yaoundé Hemophilia Treatment Center (HTC) of Cameroon multiple cases of hemophilia and von willebrand disease (VWD) were registered.       

Market Segments:   

On the basis of drug class which comprises of coagulation factor which is further sub-segmented into plasma derived and recombinant coagulation factor; vitamin K analogues, fibrinogen analogues and others.

UAE is the largest market for blood coagulant drugs in Middle East and Africa’s market of blood coagulating drugs closely followed by Egypt. Middle East and Africa blood coagulants market has been segmented

clinical indications; market is segmented into accidents, surgery, hemophilia and others.  

Browse Report @ https://www.marketresearchfuture.com/reports/blood-coagulants-market-2743 .

Key Findings:

MEA blood coagulants market for hemophilia segment was estimated to be USD 31.55 million in 2016

UAE is the fastest growing region in the MEA market and projected to grow at a CAGR of 10.1% during forecast period

Hemophilia segment dominates the market with nearly 45.5% share of the MEA market

MEA blood coagulation market is projected to reach about USD 141.68 million by 2023

Regional Analysis of Middle East and Africa Blood Coagulants Market:  

Another market that has witnessed good growth rates is Saudi Arabia, because of the greater expenditure on health by the local government and the rise in per capita income of the people. Noteworthy markets in Africa include South Africa and Algeria. The demand for these products have given rise to many biotechnological firms especially in India. The rest of Africa market is however the fastest growing with a huge unmet medical needs.

The market for blood coagulants favors organizations with solid innovative research and hello there tech in-house abilities. The market mirrors an oligopolistic nature with a couple of players ruling the market.

Huge Companies Participated for Middle East and Africa Blood Coagulants Market:   

Some of the major players in this market: Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), and CSL Limited (Australia)

Get Discount for this Report @ https://www.marketresearchfuture.com/check-discount/2743 .

Study Aims Middle East and Africa Blood Coagulants Market:

To provide detail analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Middle East and Africa blood coagulants market

Analyze the market based on various factors- price analysis, supply chain analysis, Porters Five Force analysis etc.

Overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Important people for the market of blood coagulants Blood coagulants are manufacturers, Blood coagulants suppliers, Private research laboratories, Research and development (R&D) companies, Market research and consulting service providers, Government research laboratories, Contract manufacturing organizations.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Akash Anand,

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.